Dr. Mikael Dolsten was appointed President of Worldwide Research & Development (WRD) in May, 2010. In this role, he has responsibility for all research at Pfizer, as well as development of all compounds through proof of concept (POC). A physician with more than 20 years experience in the pharmaceutical industry, Mikael oversees thousands of world-class scientists and researchers progressing a portfolio of high-impact medicines and vaccines to transform patients' lives.
Pfizer scientists across WRD apply industry-leading scientific and technology expertise across a range of small molecule and biologic platforms and modalities. In a global network of research laboratories and clinical study sites, Pfizer R&D professionals and business unit colleagues focus on translating deep science into safe and effective drugs to prevent, treat and cure disease.
Mikael oversees all Pfizer research units and biotech units in PharmaTherapeutics and BioTherapeutics: Antibacterials; Allergy & Respiratory; Cardiovascular, Metabolic & Endocrine Diseases; Neuroscience; Oncology; Pain; Regenerative Medicine; Indications Discovery; Inflammation & Immunology; Tissue Repair; BioCorrection; Orphan & Genetic Diseases; New Opportunities; Therapeutic Innovation Laboratories; Vaccine R&D; CovX; Rinat; Oligonucleotide Therapeutics; and the Center for Integrative Biology & Biotherapeutics.
WRD also includes these global science-based groups: Medicinal Chemistry; Drug Safety R&D; Pharmaceutical Sciences; Pharmacokinetics, Dynamics & Metabolism; Comparative Medicine; Clinical Research; Clinical Programs; Development Operations; Development & Strategic Operations; External R&D Innovation; Research Centers of Emphasis; and Asia R&D.
Previously, Mikael was President of BioTherapeutics R&D, responsible for driving Pfizer leadership, expertise, and innovation in biologic medicines and vaccines.
Prior to joining Pfizer in 2009, Mikael was Senior Vice President, Wyeth Inc. and President of Wyeth Research where he led scientists across the U.S., Europe and Asia in the research and development of small molecules, vaccines and protein-based medicines in Inflammation, Women Health's, Neuroscience, Oncology, Infectious diseases (vaccines, antibiotics), Hemophilia, GI and Musculoskeletal diseases.
Before joining Wyeth, Mikael served as Executive Vice President within Pharmaceutical Research & Development/Medicine at Boehringer Ingelheim. He led pharmaceutical research in the U.S., Canada, Germany, Italy, Austria and Japan - with programs in respiratory, inflammation/immunology, oncology, virology, cardiovascular, metabolism and CNS. He was a member of the BI corporate management team responsible for all worldwide development projects and licensing opportunities. Mikael's earlier career included research leader positions with AstraZeneca, Pharmacia and Upjohn.
Mikael earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden. He also studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund.
In July 2010, Mikael was elected a fellow of the New York Academy of Medicine. He is an appointed Governor of the New York Academy of Sciences. A member of the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA), Mikael also serves on the PhRMA Foundation Board of Directors.
Mikael has published several patents and about 150 articles in international journals with particular contributions in areas such as molecular cell biology, immunology and oncology.